Premium
Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia
Author(s) -
Kucine Nicole,
Bergmann Shayla,
Krichevsky Spencer,
Jones Devin,
Rytting Michael,
Jain Juhi,
Bennett Carolyn M.,
Resar Linda M.S.,
Mascarenhas John,
Verstovsek Srdan,
Hoffman Ronald
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28888
Subject(s) - medicine , essential thrombocythemia , polycythemia vera , thrombocytosis , pegylated interferon , alpha interferon , anagrelide , interferon , pediatrics , immunology , ribavirin , platelet , hepatitis c virus , virus
Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.